Skip to main content
. Author manuscript; available in PMC: 2023 Jan 28.
Published in final edited form as: Haemophilia. 2019 Jul;25(4):581–589. doi: 10.1111/hae.13717

FIGURE 3.

FIGURE 3

Clinical Trial Concept 2: Inhibitor Eradication Gene Therapy Immune Tolerance Induction Trial. Subjects with severe haemophilia A and inhibitors receive AAV-hFVIII gene therapy and emicizumab or bypass (rFVIIa or FEIBA), and are followed for inhibitor resolution, <0.6 BU, at prespecified time-points